Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

The t(11;14)(q13;q32) results in up-regulation of cyclin D1 and is the most common translocation detected in multiple myeloma, where it is also associated with a lymphoplasmacytic morphology. We performed an interphase fluorescent in situ hybridization (FISH) study to determine the clinical and biologic significance of the abnormality when testing a large cohort of myeloma patients. Bone marrow slides from multiple myeloma patients entered into the Eastern Cooperative Oncology Group phase III clinical trial E9486 and associated laboratory correlative study E9487 were analyzed using interphase FISH combined with immune-fluorescent (cytoplasmic immunoglobulin-FISH) detection of clonal plasma cells. We used FISH probes that hybridize to the 14q32 and 11q13 chromosomal loci. The t(11;14)(q13;q32) was correlated with known biologic and prognostic factors. Of 336 evaluable patients, 53 (16%) had abnormal FISH patterns compatible with the t(11;14)(q13;q32). These patients appeared to be more likely to have a serum monoclonal protein of less than 10 g/L (1 g/dL) (28% vs 15%, P =.029) and a lower plasma cell labeling index (P =.09). More strikingly, patients were less likely to be hyperdiploid by DNA content analysis (n = 251, 14% vs 62%, P <.001). Patients with the t(11;14)(q13;q32) appeared to have better survival and response to treatment, although this did not reach statistical significance. Multiple myeloma with the t(11;14)(q13;q32) is a unique subset of patients, not only characterized by cyclin D1 up-regulation and a lymphoplasmacytic morphology, but is also more frequently associated with small serum monoclonal proteins and is much less likely to be hyperdiploid. These patients do not have a worsened prognosis as previously thought.

[1]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[2]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.

[3]  R. Fonseca,et al.  Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy , 2001, Leukemia.

[4]  P. L. Bergsagel,et al.  IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc. , 1997, Current topics in microbiology and immunology.

[5]  P. L. Bergsagel,et al.  Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. , 1999, Molecular cell.

[6]  M. Rocchi,et al.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). , 2000, The American journal of pathology.

[7]  D. Gerhard,et al.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. , 1996, Blood.

[8]  W. Kuehl,et al.  Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Bataille,et al.  Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Blood.

[10]  E. Schuuring,et al.  Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. , 1996, Blood.

[11]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[12]  M. Vasef,et al.  Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[13]  R. Bataille,et al.  Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. , 2001, Blood.

[14]  R. Fonseca,et al.  Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. , 1999, Cancer genetics and cytogenetics.

[15]  E. Schröck,et al.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.

[16]  M. Oken,et al.  The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma , 1999, Cancer.

[17]  G. Ahmann,et al.  Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. , 1999, Leukemia & lymphoma.

[18]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[19]  B. Barlogie,et al.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Bataille,et al.  14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Cancer research.

[21]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[22]  E. Schuuring,et al.  Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. , 1995, Blood.

[23]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  R. Fonseca,et al.  Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases , 1998, British journal of haematology.

[26]  David R. Cox.  The analysis of binary data , 1970 .

[27]  M. Oken,et al.  Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? , 1999, Leukemia & lymphoma.

[28]  G. Ahmann,et al.  A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. , 1998, Cancer genetics and cytogenetics.

[29]  H. Avet-Loiseau,et al.  Expression of cyclins D-type in B-chronic lymphoproliferative disorders , 2000, Leukemia.

[30]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[31]  M. Seto,et al.  Selective usage of D-type cyclins in lymphoid malignancies , 1999, Leukemia.

[32]  P. L. Bergsagel,et al.  Promiscuous translocations into igh switch regions: The genetic hallmark of multiple myeloma , 1996 .

[33]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[34]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[35]  R. Bataille,et al.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. , 1998, Cancer research.

[36]  H. Kittler,et al.  Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Bastard,et al.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.

[38]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[39]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[40]  G. Ahmann,et al.  Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. , 2001, Blood.

[41]  A. Jauch,et al.  Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). , 2000, Blood.

[42]  R. Fonseca,et al.  The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. , 2000, American journal of clinical pathology.

[43]  E. Schuuring,et al.  Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization. , 1996, Blood.